CANCER SCREENING
Educational resources
Here is more information to educate your patients and the rest of your practice about the benefits of the Shield™ blood test and the importance of early CRC screening
Here is more information to educate your patients and the rest of your practice about the benefits of the Shield™ blood test and the importance of early CRC screening
sensitivity for advanced adenomas
sensitivity for high-grade dysplasia
negative predictive value*
* The probability that a negative test result is truly negative.6
Sensitivity based on stage at diagnosis7†
†Excludes 2 CRC stage unknown (1/2 detected)
‡Assumes 5 incompletely staged by AJCC malignant polyps are Stage 1 disease
AJCC=American Joint Committee on Cancer.
The Shield MCD results report is not a part of the FDA approved Shield IVD and has not been cleared or approved by the FDA.
| Tumor type | Sensitivity | Primary CSO Accuracy |
|---|---|---|
| Bladder | 62% | 75% |
| Breast | 45% | 97% |
| CRC | 83% | 88% |
| Esophageal/Gastric (Stomach) | 96% | 78% |
| Liver (Hepatocellular) | 94% | 60% |
| Lung | 67% | 95% |
| Ovarian | 70% | 100% |
| Pancreatic | 67% | 77% |
| Prostate | 21% | 92% |
Overall specificity across all cancers:
98.6%
CRC = colorectal cancer; CSO = cancer signal origin; MCD = multi-cancer detection.